Last edition
News about
Granules India secures Sole First-to-File ANDA status for Sodium Oxybate Extended-Release for Oral Suspension, strengthening its US complex generics portfolio.
Glenmark Pharmaceuticals Launches Olanzapine for Injection 10 mg/vial Single-Dose Vial in US
Glenmark Pharmaceuticals Inc., USA has launched Olanzapine for Injection 10 mg/vial, a bioequivalent and therapeutically equivalent generic to Zyprexa IntraMuscular Injection.
SK Bioscience Launches AI-Powered Initiative to Reduce Uncertainty in Vaccine-Development Decisions
SK bioscience has launched an Artificial Intelligence (AI)-powered initiative to improve vaccine development decisions, supporting next-generation injectable rotavirus vaccines and expanding access in Low- and Middle-Income Countries (LMICs).
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib
Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.
Eisai seeks UK Approval for Insomnia Therapy Lemborexant
Eisai has submitted lemborexant for regulatory review in the UK, aiming to expand treatment options for adults suffering from chronic insomnia and improve patients' daytime functioning.
HUTCHMED Secures NMPA Approval for ORPATHYS in Gastric Cancer
HUTCHMED has received NMPA approval for ORPATHYS, the first selective MET inhibitor in China for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma.
Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer
Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.
Otsuka's Voyxact Phase 3 Trial Shows Long-Term Kidney Protection in IgA Nephropathy
Otsuka's Voyxact delivered significant long-term kidney function stabilization and reduced the risk of kidney failure in the Phase 3 VISIONARY trial, strengthening its potential as a disease-modifying treatment for IgA nephropathy.
Vyome Secures China Patent for Besifloxacin Topical Gel in Inflammatory Acne Treatment
Vyome Holdings has secured a Chinese patent for its proprietary besifloxacin topical gel programme, strengthening intellectual property protection for inflammatory acne treatment and expanding future commercial opportunities in one of the world's largest dermatology markets.
Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial
Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy